Suppr超能文献

血液 Krebs von den Lungen-6 的变化可预测间质性肺疾病急性加重患者的死亡率。

Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease.

机构信息

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.

出版信息

Sci Rep. 2022 Mar 22;12(1):4916. doi: 10.1038/s41598-022-08965-9.

Abstract

Acute exacerbation (AE) significantly affects the prognosis of patients with interstitial lung disease (ILD). This study aimed to investigate the best prognostic biomarker for patients with AE-ILD. Clinical data obtained during hospitalization were retrospectively analyzed for 96 patients with AE-ILD at three tertiary hospitals. The mean age of all subjects was 70.1 years; the percentage of males was 66.7%. Idiopathic pulmonary fibrosis accounted for 60.4% of the cases. During follow-up (median: 88 days), in-hospital mortality was 24%. Non-survivors had higher lactate dehydrogenase and C-reactive protein (CRP) levels, lower ratio of partial pressure of oxygen to the fraction of inspiratory oxygen (P/F ratio), and higher relative change in Krebs von den Lungen-6 (KL-6) levels over 1 week after hospitalization than survivors. In multivariable analysis adjusted by age, the 1-week change in KL-6-along with baseline P/F ratio and CRP levels-was an independent prognostic factor for in-hospital mortality (odds ratio 1.094, P = 0.025). Patients with remarkable increase in KL-6 (≥ 10%) showed significantly worse survival (in-hospital mortality: 63.2 vs. 6.1%) than those without. In addition to baseline CRP and P/F ratio, the relative changes in KL-6 over 1 week after hospitalization might be useful for predicting in-hospital mortality in patients with AE-ILD.

摘要

急性加重(AE)显著影响间质性肺疾病(ILD)患者的预后。本研究旨在探讨 AE-ILD 患者最佳预后生物标志物。对三家三级医院 96 例 AE-ILD 住院患者的临床资料进行回顾性分析。所有患者的平均年龄为 70.1 岁,男性占 66.7%。特发性肺纤维化占 60.4%。随访(中位数:88 天)期间,住院死亡率为 24%。与幸存者相比,非幸存者的乳酸脱氢酶和 C 反应蛋白(CRP)水平更高,氧分压与吸入氧分数的比值(P/F 比值)更低,住院后 1 周内 Krebs von den Lungen-6(KL-6)水平的相对变化更大。经年龄调整的多变量分析,住院后 1 周 KL-6 的变化与基线 P/F 比值和 CRP 水平一起是住院死亡率的独立预后因素(优势比 1.094,P=0.025)。KL-6 显著增加(≥10%)的患者的生存率明显更差(住院死亡率:63.2%比 6.1%)。除基线 CRP 和 P/F 比值外,住院后 1 周内 KL-6 的相对变化可能有助于预测 AE-ILD 患者的住院死亡率。

相似文献

2
Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
PLoS One. 2020 Dec 17;15(12):e0244114. doi: 10.1371/journal.pone.0244114. eCollection 2020.
4
Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease.
PLoS One. 2020 Mar 12;15(3):e0229997. doi: 10.1371/journal.pone.0229997. eCollection 2020.
7
Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Rheumatol Int. 2018 May;38(5):813-819. doi: 10.1007/s00296-018-3987-3. Epub 2018 Feb 17.
8
Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
Arch Bronconeumol. 2024 Jun;60(6):350-355. doi: 10.1016/j.arbres.2024.03.028. Epub 2024 Apr 6.
10

引用本文的文献

1
Role of blood Krebs von Lungen-6 in predicting acute exacerbation in patients with idiopathic pulmonary fibrosis.
PLoS One. 2025 May 30;20(5):e0323784. doi: 10.1371/journal.pone.0323784. eCollection 2025.
3
5
Krebs von den Lungen-6 (KL-6) as a diagnostic and prognostic biomarker for non-neoplastic lung diseases.
Clin Chem Lab Med. 2024 Nov 27;63(5):923-930. doi: 10.1515/cclm-2024-1089. Print 2025 Apr 28.
9
Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers.
Int J Mol Sci. 2023 Jun 15;24(12):10196. doi: 10.3390/ijms241210196.
10
Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice.
Int J Mol Sci. 2022 Nov 30;23(23):15027. doi: 10.3390/ijms232315027.

本文引用的文献

2
Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.
Am J Respir Crit Care Med. 2020 Aug 1;202(3):e36-e69. doi: 10.1164/rccm.202005-2032ST.
4
Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease.
PLoS One. 2020 Mar 12;15(3):e0229997. doi: 10.1371/journal.pone.0229997. eCollection 2020.
6
Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 1. Introduction.
Tuberc Respir Dis (Seoul). 2019 Oct;82(4):269-276. doi: 10.4046/trd.2018.0090. Epub 2019 May 31.
7
Sequential changes of serum KL-6 predict the progression of interstitial lung disease.
J Thorac Dis. 2018 Aug;10(8):4705-4714. doi: 10.21037/jtd.2018.07.76.
8
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.
9
Acute Exacerbation in Interstitial Lung Disease.
Front Med (Lausanne). 2017 Oct 23;4:176. doi: 10.3389/fmed.2017.00176. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验